Drug Executive Collapses During Oval Office Press Conference
During a press conference in the Oval Office, a drug executive fainted while President Donald Trump was announcing a deal with pharmaceutical companies to reduce obesity drug prices.
Incident Details
The event was focused on a new agreement between Trump and drugmakers Eli Lilly and Novo Nordisk to expand insurance coverage and lower costs for popular obesity treatments, Zepbound and Wegovy. David Ricks, CEO of Eli Lilly, noticed the executive's distress and asked,
“Are you okay? Gordon, are you okay?”
The man who collapsed was identified as Gordon Findlay, global brand director at Novo Nordisk.
Immediate Response
Dr. Mehmet Oz, Administrator for the Centers for Medicare & Medicaid Services, reacted quickly as Findlay fell to his knees. Other officials, including the Health and Human Services Secretary, were present during the incident. The press was then asked to leave the room briefly.
Aftermath
About 30 minutes later, the press conference resumed and President Trump provided an update on Findlay's condition.
“We had a situation, but everything is going to be fine.”
Summary
The event highlighted both a significant drug pricing agreement and the quick response of medical professionals when a health emergency occurred during a high-profile announcement.
Author’s summary: A drug executive collapsed during President Trump’s announcement on reducing obesity drug prices, but was promptly assisted, and the event resumed with an update on his health.